Phase II study of Carboplatin, weekly Paclitaxel and Bevacizumab in elderly patients with advanced non-squamous non-small-cell lung cancer (NEJ 016)

Phase 2

• Conditions: non-small cell lung cancer

• Registration Number: JPRN-UMIN000006622
• Lead Sponsor: orth East Japan Study Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-10-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

1) History of hemoptysis 2) High risk of bleeding or thrombus events 3) History of anticoagulant within 10 days before enrollment 4) Grade 2 or worse neuropathy 5) Uncontrollable hypertension 6) Symptomatic brain metastasis 7) Uncontrollable pleural effusion or peritoneal effusion 8) Scheduled operation 9) Severe complications 10) Severe infection 11) History of active double cancer 12) No intention to birth control 13) Unstable psychic disorder 14) History of treatment drug 15) History of severe allergic reaction with platinum drug or monoclonal antibody 16) History of allergic reaction with taxan drug, polyoxyethylene or alcohol. 17) Decision of ineligibility by a physician.

Study & Design

• Study Type: Interventional
• Study Design: Not specified